• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » BioClinica posts Q4 profit, sales increase

BioClinica posts Q4 profit, sales increase

February 10, 2010 By MassDevice staff

BioClinica Inc. (NSDQ:BIOC) posted fourth-quarter sales of $20.2 million for the three months ended Dec. 31, 2009, up 14.3 percent compared with $17.7 million during the same period in 2008. Net income reached $943,000, compared with a net loss of $171,000 during Q4 2008:

Press Release

BioClinica Announces Fourth Quarter and Year End 2009 Financial
Results

NEWTOWN, Pa.–(BUSINESS WIRE)–BioClinica™, Inc. (NASDAQ: BIOC), a global provider of clinical trial
services, today announced its financial results for the quarter and year
ended December 31, 2009. The operating results of Phoenix Data Systems
(“PDS”) are included in the financial results following the acquisition
of PDS that was completed March 24, 2008. The CapMed division, which was
sold on January 6, 2009, was reclassified as a discontinued operation
for all periods presented.

Financial highlights for the quarter ended December 31, 2009 include:

  • Service revenues were $14.9 million as compared with $15.0 million for
    the same period 2008.
  • GAAP income from continuing operations before interest and taxes was
    $1.6 million as compared with $2.3 million for the same period 2008.
  • GAAP income from continuing operations, net of taxes was $943,000, or
    $0.06 per fully diluted share, as compared with $1.7 million, or $0.11
    per fully diluted share, for the same period 2008.
  • Non-GAAP income from continuing operations before interest and taxes
    was $2.0 million as compared with $2.4 million for the same period
    2008.
  • Non-GAAP income from continuing operations, net of taxes was $1.2
    million, or $0.08 per fully diluted share, as compared with $1.8
    million, or $0.12 per fully diluted share, for the same period 2008.
  • Backlog was $98.7 million as of December 31, 2009 as compared with
    $96.5 million at September 30, 2009 and compared with $92.7 million as
    of December 31, 2008.

Financial highlights for the year ended December 31, 2009 include:

  • Service revenues reached a record $57.4 million as compared with $56.2
    million for the same period 2008.
  • GAAP income from continuing operations before interest and taxes was
    $4.7 million as compared with $8.5 million for the same period 2008.
  • GAAP income from continuing operations, net of taxes was $3.0 million,
    or $0.20 per fully diluted share, as compared with $5.8 million, or
    $0.40 per fully diluted share, for the same period 2008.
  • Non-GAAP income from continuing operations before interest and taxes
    was $7.1 million as compared with $9.4 million for the same period
    2008.
  • Non-GAAP income from continuing operations, net of taxes was $4.5
    million or $0.30 per fully diluted share, as compared with $6.4
    million, or $0.44 per fully diluted share, for the same period 2008.

Mark L. Weinstein, President and Chief Executive Officer of BioClinica
said, “As we enter our twentieth year of business, I am extremely proud
to be the CEO of BioClinica, a leader in our industry. We offer a suite
of integrated services including medical image management, electronic
data capture, data management, IVR/IWR, clinical supply optimization and
other eClinical services. Despite difficult market conditions, we
reflect positively upon the successes that we achieved during the last
year, including record service revenue. Among the many highlights for
the year were the acquisitions of Tourtellotte Solutions and CardioNow,
as well as our rebranding into BioClinica. The two acquisitions
complemented and increased our suite of services, and the integration of
both companies into BioClinica has been very successful. BioClinica
Optimizer, a clinical supply forecasting and optimization product, has
an established presence in four of the top 10 pharmaceutical companies
and there are many discussions underway with other companies.
Additionally, our team is completing the development of our Trident
IVR/IWR which will be launched this summer. Further, our rebranding has
also met with great success, and I am pleased to note that our brand
recognition today is as high as it was before the rebranding took place
last April. Customers and potential customers alike have a high
awareness level of our new name, and with that, comes the value of our
brand equity that translates into high-quality, cost-effective and
best-in-class solutions.”

“The increases in market activity that began late last year have
continued into the first quarter of 2010 and have resulted in an
increased level of proposal activity,” Mr. Weinstein continued.
“Company-wide, we have increased and strengthened the component
offerings in our suite of clinical trial services, and we have also
benefited from the continued trends in the pharmaceutical industry to
outsource their clinical trials services to companies such as
BioClinica. With an established and growing global presence, 20 years of
experience and a stellar reputation in the industry, we believe
BioClinica will continue to benefit from these changing industry trends.
Our balance sheet remains strong and we continue to seek acquisitions
that will enable us to strengthen our products and services, while also
helping us to increase our market share.”

Mr. Weinstein concluded, “With our strengthened offerings, increased
proposal activity and our improved backlog, we expect full-year 2010
service revenue to be in the range of $61 to $65 million and non-GAAP
EPS to be in the range of $0.33 to $0.37 per share, which equates to
GAAP EPS in the range of $0.25 to $0.29 per share.”

Filed Under: Business/Financial News, News Well, Research & Development Tagged With: BioClinica Inc.

More recent news

  • Neuronetics names Steven Pfanstiel chief financial officer
  • Medtronic to distribute Future Medical’s peripheral guidewires
  • AtriCure completes enrollment in stroke prevention trial
  • GT Medical raises $53M to support brain tumor treatment
  • Imperative Care, Proximie partner to develop surgical robot to treat stroke

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy